Fig. 2From: Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort studyKaplan Meier survival curves of overall survival (all patients; RAS/BRAF wild-type; BRAF mutant; RAS mutant)Back to article page